Navigation Links
Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of the Phase 2 proof-of-concept data from the Anthem (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June 26th issue of the Journal of of Cardiology (JACC), demonstrating that higher-dose (greater than or equal to 7.5 mcg/kg) recombinant nematode anticoagulant protein c2 (rNAPc2) reduced the incidence and duration of ischemia as measured by 7-day continuous electrocardiogram (ECG) by more than 50% and did not statistically significantly increase bleeding in patients being treated with standard antithrombotics and an early invasive approach for non-ST-elevation acute coronary syndromes (NSTE-ACS).

"In clinical studies of other antithrombotics, suppression of ischemia monitored by continuous ECG has been associated with a reduction in clinical ischemic events," said Dr. Robert Giugliano, M.D., S.M., Investigator, TIMI Study Group, Associate Physician, Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. "In the ANTHEM/TIMI 32 trial, the ability of higher-dose rNAPc2 to reduce ischemia in patients that are already receiving antithrombotic therapy is very exciting, and we look forward to future studies to further understand rNAPc2's potential in this patient population."

ANTHEM/TIMI 32 Study Details and Results

The ANTHEM/TIMI 32 trial consisted of two stages, a dose escalation safety stage and a heparin replacement stage. All patients in the study had 3-lead Holter monitors for assessment of cardiac ischemia, measurement of prothrombin time and F1+2 concentration, and clinical follow-up for up to six months.

The first stage was a double-blind, placebo-controlled, dose escalation study which investigated the safety of rNAPc2 in combination with other antithrombotics in 203 patients with NSTE-ACS. These dat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/30/2015)... and VANCOUVER , July 30, 2015 ... today that it will report its second quarter 2015 ... will host a conference call and live webcast at ... financial results, clinical development programs and a general corporate ... on to the Investor Relations page of the OncoGenex ...
(Date:7/30/2015)... FALLS, Ohio , July 30, 2015  Cleveland ... his OMTEC® 2015 keynote address last month that industry ... models in order to gain the efficiencies—and develop the ... Dr. Barsoum,s comments were preceded by ... avid entrepreneur and OMTEC moderator, who stressed that industry ...
(Date:7/30/2015)...  Medimetriks Pharmaceuticals, Inc. announced today that its ... study for Ozenoxacin, a novel bactericidal non-fluorinated quinolone ... U.S. rights to Ozenoxacin 1% cream.  ... with an emphasis on U.S. patients, involved 412 ... older with a clinical diagnosis of bullous or ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... today announced the national availability and receipt of ... pain medication monitoring program offering the industry,s highest ... and identify potential negative drug interactions before they ... concerns of prescription pain medication abuse by using ...
... ISIS ), the leader in antisense therapeutics, today ... Goldman Sachs 33rd Annual Global Healthcare Conference on Tuesday, June ... in Rancho Palos Verdes, CA. A live audio ... & Media" section of the Company,s Web site, www.isispharm.com ...
Cached Medicine Technology:PeaceHealth Laboratories' New Patent Addresses a Leading Cause of Death: Prescription Drug Abuse 2
(Date:7/31/2015)... ... ... a reputable source of authentic USA vs. Australia tickets at Ford Field in ... in conjunction with their Victory Tour to celebrate winning the 2015 Women's World Cup by ... awarded the Golden Ball as the best player of the 2015 Women's World Cup. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the ... Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is ... providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... McLean, VA (PRWEB) , ... July 31, 2015 , ... ... solution at OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) ... (IaaS) and software as a service (SaaS). , HITaaS manages all aspects ...
(Date:7/31/2015)... ... ... Physical therapy for knee osteoarthritis is an important part of knee ... patient from doing what they want or need to do. The patient may have trouble ... The patient's exercise regime may be limited by the pain in their knee. When a ...
(Date:7/31/2015)... McMinnville, OR (PRWEB) , ... July 31, 2015 , ... ... the Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – ... is an exciting and important day for the entire community as the culmination of ...
Breaking Medicine News(10 mins):Health News:Cheap USA vs. Australia Tickets at Ford Field in Detroit, MI: Ticket Down Slashes Ticket Prices for Australia vs. USWNT International Friendly Match at Ford Field 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... 2010 Elsevier, a world-leading publisher of scientific, ... announced the launch of SciVerse, an innovative platform ... the scientific community to collaborate on the development ... committed to releasing the APIs (application programming interfaces) ...
... French . The medicinal use of cannabis has ... large for many years as an alternative to standard pharmaceutical ... may have unwanted side effects. A new study by McGill ... that cannabis may offer relief to patients suffering from chronic ...
... , SUNDAY, Aug. 29 (HealthDay News) -- Having a particular ... risk of getting migraines, new research shows. While migraines ... specific genes has proven difficult, the researchers said. The ... genetic variant associated with a heightened risk for the most ...
... people suffering chronic pain, smoked cannabis reduces pain, ... research published in CMAJ (Canadian Medical Association Journal) ... who suffer from chronic neuropathic pain due to ... few treatment options. These options include opioids, anticonvulsants, ...
... Many children are being put at risk by parents over-use ... and colds, says a study from Australia to be presented ... today (Monday 30 August). The researchers, led ... South Wales, say that dosing errors and inappropriate use of ...
... FRIDAY, Aug. 27 (HealthDay News) -- While attention-deficit hyperactivity disorder ... there is a cluster of kids and adults who successfully ... privileges in school. "People who want to fake ADHD ... on a number of standard clinical instruments that are used ...
Cached Medicine News:Health News:Elsevier introduces SciVerse, an innovative platform for accelerating science 2Health News:Research demonstrates benefits of medical cannabis as a treatment for chronic pain 2Health News:New Migraine Gene Discovered 2Health News:New Migraine Gene Discovered 3Health News:Smoked cannabis reduces chronic pain 2Health News:Widespread parental misuse of medicines puts children at risk 2Health News:Widespread parental misuse of medicines puts children at risk 3Health News:Some Fake ADHD to Get Meds, Special Treatment 2Health News:Some Fake ADHD to Get Meds, Special Treatment 3
Hartman Mosquito forceps, straight, 3.5"....
Curved 20 mm serrated jaws. Ring handle with ratchet lock and dull finish. Most popular size or model. Overall length 3.9 inches...
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Straight shafts with 16 mm long platform. Lengthwise serrated jaws with cross serrated tips. Serrated handle with polished finish. Platform: 2.4 mm wide....
Medicine Products: